Abstract
Matrix metalloproteinases (MMPs) are of crucial importance for the invasive behavior of primary tumors and their metastases. MMP activity is regulated by the four naturally occurring tissue inhibitors of metalloproteinases (TIMPs). It has been shown that overexpression of TIMPs in tumors of various origins leads to reduced tumor growth and formation of metastases. More recently, antitumor efficacy by in vivo gene transfer of TIMPs has been reported in several clinically relevant animal models. This review analyses the therapeutic potential of the TIMPs from a cancer gene therapeutic point of view with particular emphasis on cell culture and in vivo data.
Keywords: Cancer Gene Therapy, Metalloproteinases, Angiogenesis, Tissue Inhibitors
Current Gene Therapy
Title: Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Volume: 2 Issue: 2
Author(s): Karsten Brand
Affiliation:
Keywords: Cancer Gene Therapy, Metalloproteinases, Angiogenesis, Tissue Inhibitors
Abstract: Matrix metalloproteinases (MMPs) are of crucial importance for the invasive behavior of primary tumors and their metastases. MMP activity is regulated by the four naturally occurring tissue inhibitors of metalloproteinases (TIMPs). It has been shown that overexpression of TIMPs in tumors of various origins leads to reduced tumor growth and formation of metastases. More recently, antitumor efficacy by in vivo gene transfer of TIMPs has been reported in several clinically relevant animal models. This review analyses the therapeutic potential of the TIMPs from a cancer gene therapeutic point of view with particular emphasis on cell culture and in vivo data.
Export Options
About this article
Cite this article as:
Brand Karsten, Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs), Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605564
DOI https://dx.doi.org/10.2174/1566523024605564 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells in Cartilage Repair: State of the Art and Methods to monitor Cell Growth, Differentiation and Cartilage Regeneration
Current Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets One Hundred Faces of Cyclopamine
Current Pharmaceutical Design MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells
Current Cancer Drug Targets Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Regulatory Mechanisms of Chondrogenesis and Implications for Understanding Articular Cartilage Homeostasis
Current Rheumatology Reviews Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Blocks Neurodegeneration through Phosphoinositide 3 Kinase/Akt1 and Apoptotic Mitochondrial Signaling Involving Bad, Bax, Bim, and Bcl-xL
Current Neurovascular Research A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Therapeutic Approach of Primary Bone Tumours by Bisphosphonates
Current Pharmaceutical Design The Roles of Endoplasmic Reticulum Stress in the Pathophysiological Development of Cartilage and Chondrocytes
Current Pharmaceutical Design Extracellular SH3 Domain Containing Proteins – Features of a New Protein Family
Current Protein & Peptide Science Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry